Brief: Kalaris Begins Phase 1b/2 Study Of TH103 For Neovascular AMD With Multiple Ascending Dose Enrollment Underway
15/09/2025 13:08
Sept 15 (Reuters) - Kalaris Therapeutics Inc KLRS.O: KALARIS THERAPEUTICS NOW ENROLLING PHASE 1B/2 MULTIPLE ASCENDING DOSE STUDY OF TH103 IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION KALARIS THERAPEUTICS INC - PHASE 1B/2 DATA EXPECTED IN 2H 2026 Source text: ID:nGNX7pwVn5 Further company coverage: KLRS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kalaris Therapeutics
See all newsKalaris Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Kalaris Therapeutics Q2 net loss narrows on lower administrative costs
Kalaris Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview
Kalaris Therapeutics posts smaller-than-expected Q1 net loss
Brief: Kalaris Therapeutics Inc Q1 Operating Income USD -11.833 Million